JPH0789914B2 - Endo type glycolipid degrading enzyme - Google Patents
Endo type glycolipid degrading enzymeInfo
- Publication number
- JPH0789914B2 JPH0789914B2 JP15099986A JP15099986A JPH0789914B2 JP H0789914 B2 JPH0789914 B2 JP H0789914B2 JP 15099986 A JP15099986 A JP 15099986A JP 15099986 A JP15099986 A JP 15099986A JP H0789914 B2 JPH0789914 B2 JP H0789914B2
- Authority
- JP
- Japan
- Prior art keywords
- ceramide
- ion
- enzyme
- glycolipid
- degrading enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004190 Enzymes Human genes 0.000 title claims description 50
- 108090000790 Enzymes Proteins 0.000 title claims description 50
- 229930186217 Glycolipid Natural products 0.000 title claims description 13
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 title claims description 12
- 230000000593 degrading effect Effects 0.000 title description 7
- 229940106189 ceramide Drugs 0.000 claims description 27
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 26
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 26
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 26
- 150000002482 oligosaccharides Chemical class 0.000 claims description 21
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 20
- 150000002339 glycosphingolipids Chemical class 0.000 claims description 15
- 235000000346 sugar Nutrition 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 13
- 229920001542 oligosaccharide Polymers 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 150000002772 monosaccharides Chemical class 0.000 claims description 9
- 229930182830 galactose Natural products 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 229930183167 cerebroside Natural products 0.000 claims description 4
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 3
- 239000013504 Triton X-100 Substances 0.000 claims description 3
- 229920004890 Triton X-100 Polymers 0.000 claims description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 3
- 229910001422 barium ion Inorganic materials 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- 229910001431 copper ion Inorganic materials 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 3
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical compound [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 claims description 3
- 229920005654 Sephadex Polymers 0.000 claims description 2
- 239000012507 Sephadex™ Substances 0.000 claims description 2
- 150000001783 ceramides Chemical class 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229920001817 Agar Polymers 0.000 description 12
- 239000008272 agar Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- 239000000049 pigment Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 241000187562 Rhodococcus sp. Species 0.000 description 6
- 125000001549 ceramide group Chemical group 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 241000187654 Nocardia Species 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- -1 G T1a Natural products 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000187603 Pseudonocardia Species 0.000 description 2
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- BBBFYZOJHSYQMW-LGDQNDJISA-N (2s)-2,4-diamino-4-oxobutanoic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC(=O)[C@@H](N)CC(N)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O BBBFYZOJHSYQMW-LGDQNDJISA-N 0.000 description 1
- UQZSVIGPZAULMV-DKWTVANSSA-N (2s)-2,4-diamino-4-oxobutanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)[C@@H](N)CC(N)=O UQZSVIGPZAULMV-DKWTVANSSA-N 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000186360 Mycobacteriaceae Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001655308 Nocardiaceae Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- NJFMNPFATSYWHB-UHFFFAOYSA-N ac1l9hgr Chemical compound [Fe].[Fe] NJFMNPFATSYWHB-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 150000002812 neutral glycosphingolipids Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000006877 oatmeal agar Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
Description
【発明の詳細な説明】 (産業上の利用分野) 本発明は糖脂質分解酵素に関する。TECHNICAL FIELD The present invention relates to a glycolipid degrading enzyme.
(従来の技術) 動物界に広く存在していることが知られているスフィン
ゴ糖脂質は、スフィンゴ塩基の第一級アルコール性水酸
基がグリコシド結合によって単糖又はオリゴ糖と結合
し、更に脂肪酸がスフィンゴ塩基に酸アミド結合したも
のであり、このスフィンゴ塩基と脂肪酸からなる部分を
セラミドと呼んでいる。(脂質の化学、365頁、1974
年、東京化学同人社発行)。(Prior Art) Glycosphingolipid, which is known to exist widely in the animal kingdom, is a glycosidic bond between a primary alcoholic hydroxyl group of a sphingo base and a monosaccharide or an oligosaccharide, and a fatty acid is a sphingoglycone. The base is an acid amide bond, and the part consisting of this sphingo base and fatty acid is called ceramide. (Lipid Chemistry, p. 365, 1974
Year, issued by Tokyo Kagaku Doujinsha).
スフィンゴ糖脂質は、細胞表層の主要な構成成分であ
り、細胞の膜抗原、血液型物質、相互識別、分化等の重
要な膜機能との関連が注目され、糖鎖の構造と機能の解
明が検討されているが、このためには、特異性の高い酵
素が重要な役割を果す。Glycosphingolipids are major constituents of the cell surface layer, and attention has been focused on their relationship with important membrane functions such as cell membrane antigens, blood group substances, mutual discrimination, and differentiation, and the structure and function of sugar chains have not been elucidated. Although being investigated, highly specific enzymes play an important role for this purpose.
(発明が解決しようとする問題点) 従来、スフィンゴ糖脂質の糖鎖切断用の酵素としては、
エキソ型糖脂質分解酵素のみが知られ、エンド型糖脂質
分解酵素は知られていない。(Problems to be Solved by the Invention) Conventionally, as enzymes for cleaving sugar chains of glycosphingolipids,
Only exo type glycolipid degrading enzyme is known, and endo type glycolipid degrading enzyme is not known.
本発明者等は、スフィンゴ糖脂質の糖鎖を切断する糖脂
質分解酵素を探索中のところ、ある種の放線菌が特異性
の高いエンド型糖脂質分解酵素を産生することを見出
し、本発明を達成したものである。The present inventors, while searching for a glycolipid degrading enzyme that cleaves the sugar chain of glycosphingolipid, found that a certain actinomycete produces highly specific endo-type glycolipid degrading enzyme. Has been achieved.
(問題点を解決するための手段) 以下本発明を詳細に説明するに、本発明のエンド型糖脂
質分解酵素は、例えば、東京都町田市で採取した土壌よ
り分離された、ロドコッカス、エスピーG−74(Rhodoc
occus sp.G−74)から取得される。この菌株は微工研菌
寄第8424号(FERMP−8424)として寄託されている。(Means for Solving Problems) In order to explain the present invention in detail, the endoglycolipid-degrading enzyme of the present invention can be used, for example, in Rhodococcus sp. G isolated from soil collected in Machida City, Tokyo. −74 (Rhodoc
occus sp. G-74). This strain has been deposited as Microorganism Research Institute No. 8424 (FERMP-8424).
上記ロドコッカスsp.G−74の形態学的特徴、各種培地上
の性状及び生理的、生化学的性質は以下に示す通りであ
る。The morphological characteristics, properties on various media and physiological and biochemical properties of Rhodococcus sp. G-74 are as shown below.
(1)形態学的特徴(ハート・インフュージョン寒天培
地上で30℃、6〜48時間培養) (イ)細胞形態:培養後、7時間位まで細胞は不均一に
伸長し、菌糸状に生育し、稀に分岐が観察される。その
後、菌糸状細胞はジグザグ状に曲がり、漸次分裂を繰り
返す。24時間以降の古い培養では、菌糸の分節(fragme
ntation)が生起し、桿状(1.6〜6.6×1.0〜1.2μm)
から球状(1.0〜1.2μm)になる。(1) Morphological characteristics (cultivated on Heart Infusion agar medium at 30 ° C. for 6 to 48 hours) (a) Cell morphology: After culturing, the cells grow nonuniformly up to about 7 hours and grow into mycelium However, bifurcation is rarely observed. After that, the mycelial cell bends in a zigzag pattern and repeats gradual division. In older cultures after 24 hours, hyphae segment (fragme
ntation) and rod-shaped (1.6-6.6 × 1.0-1.2 μm)
To spherical (1.0 to 1.2 μm).
(ロ)分裂様式:スナッピング(snapping)型 (ハ)運動性:なし (ニ)胞子形成:なし (ホ)グラム染色性:陽性 (ヘ)抗酸性:弱い抗酸性 (2)各種培地上の性状 (イ)30℃のシュクロース−硝酸塩寒天培地:生育微
弱;コロニー色は無色;気中菌糸なし;拡散性色素なし (ロ)30℃のグルコース−アスパラギン寒天培地:生育
微弱;コロニー色は無色;気中菌糸なし;拡散性色素な
し (ハ)30℃のグリセリン−アスパラギン寒天培地:生育
微弱;コロニー色は無色;気中菌糸なし;拡散性色素な
し (ニ)30℃のスターチ寒天培地:生育微弱;コロニー色
は無色;気中菌糸なし;拡散性色素なし (ホ)30℃のチロシン寒天培地:生育微弱;コロニー色
は無色;気中菌糸なし (ヘ)30℃の普通寒天培地:生育良好;コロニー色は黄
味白色に近い薄橙色;気中菌糸なし;拡散性色素なし (ト)30℃のイースト−麦芽寒天培地:生育良好;コロ
ニー色はにぶ橙色;気中菌糸なし;拡散性色素なし (チ)30℃のオートミール寒天培地:生育微弱;コロニ
ー色は無色;気中菌糸なし;拡散性色素なし (3)生理的性質 (イ)生育温度範囲(ハートインフュージョン寒天培
地) :10〜37℃ (ロ)空気中での発育 :良好 (ハ)嫌気条件下での発育 :生育せず (ニ)カタラーゼ :陽性 (ホ)オキシダーゼ :陽性 (ヘ)O−Fテスト :陰性 (ト)酸の生成(グルコース) :陰性 (チ)ゼラチンの液化 :陰性 (リ)スターチの加水分解 :陰性 (ヌ)脱脂牛乳の凝固、ペプトン化:陰性 (ル)リトマスミルク:変化なし (オ)メラニン様色素の生成(チロシン寒天培地及びペ
プトン−イースト鉄寒天培地):陰性 (ワ)糖類の資化性(プリドハム−ゴトリーブ寒天培地
上で30℃、21日間培養): L−アラビノース − D−キシロース − D−グリコース + D−フラクトース ± シュクロース − イノシトール − L−ラムノース − ラフィノース − D−マンニット − (4)生化学的性質 (イ)DNAの塩基組成GC含量:69.5% (ロ)細胞壁の主要なアミノ酸組成:DL−ジアミノピメ
リン酸 (ハ)グリコレート・テスト:グリコリル型 (ニ)ミコール酸の総炭素数:C40〜C46 (5)分類学的考察 [高次の分類学上の位置] 本菌株は、セルサイクル(cell cycle)に多形性を示
し、培養初期に菌糸状に生育し、古い培養では菌糸の断
裂が起って桿状〜球状の細胞になり、細胞の分裂様式は
スナッピング(snapping)型を示す。またグラム染色性
は強い陽性を示し、抗酸性染色は弱陽性を呈する。更に
本菌のDNAのGC含量は69.5%と高いGC量を示し、細胞壁
の主要なアミノ酸組成はDL−ジアミノピメリジン酸を有
し、ペプチドグリカン糖鎖部はグリコリル型を示す。(B) Division mode: snapping type (c) Motility: None (d) Spore formation: None (e) Gram stainability: Positive (f) Anti-acidity: Weak anti-acidity (2) Properties on various media (A) Sucrose-nitrate agar medium at 30 ° C: weak growth; colony color is colorless; no aerial hyphae; no diffusible pigment (b) glucose-asparagine agar medium at 30 ° C: weak growth; colony color is colorless; No aerial hyphae; no diffusible pigment (c) 30 ° C glycerin-asparagine agar medium: weak growth; colony color is colorless; no aerial hyphae; no diffusible pigment (d) 30 ° C starch agar medium: weak growth Colony color is colorless; no aerial hyphae; no diffusible pigment (e) Tyrosine agar at 30 ° C: weak growth; colony color is colorless; aerial hyphae (f) normal agar at 30 ° C: good growth; Colony color is yellowish white Near pale orange; no aerial hyphae; no diffusible pigment (g) 30 ° C yeast-malt agar medium: good growth; colony color is nib orange; no aerial hyphae; no diffusible pigment (H) 30 ° C Oatmeal agar medium: weak growth; colony color is colorless; no aerial hyphae; no diffusible pigment (3) Physiological properties (a) Growth temperature range (heart infusion agar medium): 10 to 37 ° C (b) in air Growth: Good (c) Growth under anaerobic conditions: No growth (d) Catalase: Positive (e) Oxidase: Positive (f) OF test: Negative (to) Acid production (glucose): Negative (H) Liquefaction of gelatin: Negative (R) Hydrolysis of starch: Negative (N) Coagulation of skim milk, peptone formation: Negative (L) Litmus milk: No change (E) Formation of melanin-like pigment (tyrosine agar medium and Peptone-E Iron iron agar): Negative (wa) Assimilation of sugars (cultivated on Pridham-Gotlieve agar for 30 days at 30 ° C): L-arabinose-D-xylose-D-glycose + D-fructose ± sucrose- Inositol-L-rhamnose-raffinose-D-mannite- (4) Biochemical properties (a) Base composition of DNA GC content: 69.5% (b) Major amino acid composition of cell wall: DL-diaminopimelic acid (c) Glyco Rate test: Total carbon number of glycolyl type (d) mycolic acid: C 40 to C 46 (5) Taxonomical consideration [Higher taxonomic position] This strain has many cell cycles. It exhibits morphology, grows in a hyphal shape at the initial stage of culture, and in old cultures, hyphal breakage occurs to form rod-shaped to spherical cells, and the cell division mode shows a snapping type. The Gram stain shows a strong positive, and the acid-fast stain shows a weak positive. Furthermore, the GC content of the DNA of this bacterium is 69.5%, which is a high GC content, the major amino acid composition of the cell wall has DL-diaminopimeridic acid, and the sugar chain of the peptidoglycan exhibits a glycolyl type.
本菌株(G−74)は、以上に示した形態的、生理的、生
化学的特性からして、ミコバクテリア科(Mycobacteria
ceae)あるいはノカルディア科(Nocardiceae)に所属
するものと考えられる。Based on the morphological, physiological and biochemical characteristics shown above, this strain (G-74) is a mycobacterial family (Mycobacteria).
ceae) or a member of the Nocardiceae family.
一方Journal of General Microbiology、71巻、77頁(1
972)の記載及びJournal of General Microbiology、88
巻、200頁(1975)の記載によれば、放線菌関連群の分
類にミコール酸の存在又はその構造をとり挙げ、これが
今日広く受け入れられている。この分類体系によれば、
ミコバクテリア科(Mycobacteriaceae)の菌C60〜C90の
炭素数のミコール酸を含有し、ノカルディア科(Nocard
iaceae)の菌はC40〜C60の炭素数のミコール酸を含有す
る。Meanwhile, Journal of General Microbiology, 71, 77 (1
972) and Journal of General Microbiology, 88.
Vol. 200, p. 1975 (1975) mentions the presence or structure of mycolic acid in the classification of actinomycetes related groups, which is widely accepted today. According to this classification system,
Containing mycolic acid carbon number of bacteria C 60 -C 90 mycobacterial family (Mycobacteriaceae), Nocardia family (NOCARD
iaceae) contains mycolic acid having a carbon number of C 40 to C 60 .
本菌株についてミコール酸の分析を行なった結果、本菌
株はC40〜C60の炭素数のミコール酸を含有していること
が判明した。よって、本菌はノカルディア科に属する菌
種であることが明らかである。As a result of analysis of mycolic acid for this strain, it was found that this strain contains mycolic acid having a carbon number of C 40 to C 60 . Therefore, it is clear that this bacterium belongs to the family Nocardia.
[属レベルの同定] バージェイのマニュアル[Bergey's Manual第8版(197
4)によれば、ノカルディア科に属するのものとして
は、ノカルディア(Nocardia)属とシュウドノカルディ
ア(Pseudonocardia)属の2属が含まれている。[Identification of genus level] Berjay's Manual [Bergey's Manual 8th Edition (197
According to 4), the genera belonging to the family Nocardia include two genera of the genus Nocardia and the genus Pseudonocardia.
とくに、ノカルディア属は培養初期の形態や気中菌糸の
有無によって3種の型に大別されていたが、今日ではこ
れ等のうちI、II型に属する菌種の多くは、形態的特
性、細胞壁組成、リン脂質、メナキノン型及びミコール
類の構造等の相違により、新属ロドコッカス(Rhodococ
cus)属に移されている。[International Journal of
Systematic Bacteriology、24巻、278頁(1970)の記
載、及びJournal of General Microbiology、100巻、99
頁(1977)の記載を参照]。In particular, the genus Nocardia was roughly classified into three types according to the morphology in the early stage of culture and the presence or absence of aerial hyphae, but today, most of these strains belonging to type I and type II have morphological characteristics. , Cell wall composition, phospholipids, menaquinone type and structures of mycols
cus) genus. [International Journal of
Systematic Bacteriology, 24, pp. 278 (1970), and Journal of General Microbiology, 100, 99
See page (1977)].
本菌株(G−74)は細胞の分裂様式から、シュウドノカ
ルディア属とは容易に区別され、C40−C46の炭素数を持
ったミコール酸を含有していることからノカルディア属
(C46−C52)とも識別される。This strain (G-74) is easily distinguished from the genus Pseudonocardia based on the cell division mode and contains mycolic acid having a carbon number of C 40 -C 46. 46- C 52 ).
以上のとおり、本菌株は、1)好気性のグラム菌であ
り、2)多形性で、3)培養初期にプリミティブ(prim
itive)な菌糸を形成し、すぐ分節して桿状〜球状にな
る。4)ミコール酸(C40−C46)を含有する、5)GC含
量69.5%の特徴を持つていること等からして、本菌株
は、ロドコッカス(Rhodococcus)属の概念に良く合致
した。As described above, this strain is 1) aerobic Gram bacteria, 2) polymorphic, and 3) primitive (prim) in the early stage of culture.
Positive hyphae are formed, and they are immediately segmented into rod-like to spherical shapes. 4) containing mycolic acid (C 40 -C 46), 5 ) and because such that with GC content 69.5% of the features, this strain was well consistent with the Rhodococcus (Rhodococcus) genus of.
よって、本菌株(G−74)は、ロドコッカスエスピー
(Rhodococcus sp.)と同定した。Therefore, this strain (G-74) was identified as Rhodococcus sp.
本発明のエンド型糖脂質分解酵素は、本発明者等によ
り、上述の菌体から産生されることが見出されたもので
ある。The endoglycolipid-degrading enzyme of the present invention has been found by the present inventors to be produced from the above-mentioned bacterial cells.
本酵素は、スフィンゴ糖脂質を基質として糖鎖とセラミ
ドの結合を切断してオリゴ糖を生成するが、単糖は生成
しない。また、単糖とセラミドとが結合したセレブロシ
ドは分解しない。This enzyme cleaves the bond between the sugar chain and ceramide using glycosphingolipid as a substrate to produce an oligosaccharide, but not a monosaccharide. Further, cerebroside in which monosaccharide and ceramide are bound is not decomposed.
より具体的には、 (1)オリゴ糖鎖中のグルコースが直接セラミドと結合
しているスフィンゴ糖脂質を基質とし、該グルコースと
セラミドの結合を切断してオリゴ糖を生成するエンド型
糖脂質分解酵素(以下酵素1という)と、 (2)オリゴ糖鎖中のガラクトースが直接セラミドと結
合しているスフィンゴ糖脂質を基質とし、該ガラクトー
スとセラミドの結合を切断してオリゴ糖を生成するエン
ド型糖脂質分解酵素(以下酵素2という)とからなる。More specifically, (1) endo-type glycolipid degradation in which glucose in an oligosaccharide chain is directly bonded to ceramide to form a glycosphingolipid as a substrate, and the bond between the glucose and ceramide is cleaved to produce an oligosaccharide. Enzyme (hereinafter referred to as Enzyme 1), and (2) Endo type that uses oligosaccharidin in which galactose in oligosaccharide chain is directly bound to ceramide as a substrate to cleave the bond between the galactose and ceramide to produce oligosaccharide. It is composed of a glycolipid degrading enzyme (hereinafter referred to as enzyme 2).
本発明の酵素1及び酵素2は、上述の菌株を培養するこ
とにより培地中に分泌されるので、培地から容易に精製
分離することができる。Since the enzyme 1 and the enzyme 2 of the present invention are secreted into the medium by culturing the above-mentioned strains, they can be easily purified and separated from the medium.
即ち、後記実施例に具体的に示すように、まず上記の菌
株の培養液を遠心分離して上清を採取し、例えば、イソ
プロパノールを加えて生成した沈澱物を採取し、適当な
溶剤で抽出し、カラムクロマトグラフィーによる精製処
理を繰返し、夫々の酵素を含む画分を採取する。That is, as specifically shown in the Examples below, first, the culture solution of the above strain is centrifuged to collect the supernatant, and for example, the precipitate formed by adding isopropanol is collected and extracted with a suitable solvent. Then, the purification treatment by column chromatography is repeated, and the fractions containing the respective enzymes are collected.
次に、酵素1及び酵素2の理化学的性質について詳細に
説明するが、酵素活性の測定は以下の方法によった。Next, the physicochemical properties of the enzyme 1 and the enzyme 2 will be described in detail. The enzyme activity was measured by the following method.
[酵素活性の測定] 酵素液 100μl 基 質 100μl [0.1Mの酢酸緩衝液(pH6.0)に5mg/mlの基質1)及び1mg
/mlのTDC(タウロデオキシコール酸ナトリウム、界面活
性剤)を加えたもの] 上記の酵素液及び基質を混合し37℃で酵素活性の強さに
応じて1時間〜1夜間反応させた後、反応液100μlを
採取し、パーク・ジョンソン(Park−Johnson)法によ
り還元力を測定し、1分間に1μmolのグルコース又は
ガラクトースに対応する還元力を生じる酵素量を1単位
とする。反応液は薄層クロマトグラフィーで分析してオ
リゴ糖及びセラミドが生じているかどうかを確認する。[Measurement of enzyme activity] Enzyme solution 100 μl Substrate 100 μl [5 mg / ml substrate 1) and 1 mg in 0.1 M acetate buffer (pH 6.0)
/ ml TDC (sodium taurodeoxycholate, surfactant) added] After mixing the above enzyme solution and substrate and reacting at 37 ° C for 1 hour to 1 night depending on the strength of the enzyme activity, 100 μl of the reaction solution is sampled and the reducing power is measured by the Park-Johnson method, and the amount of the enzyme that produces the reducing power corresponding to 1 μmol of glucose or galactose per minute is defined as 1 unit. The reaction solution is analyzed by thin layer chromatography to confirm whether oligosaccharides and ceramide are produced.
基質1):酵素1の場合には、牛脳から単離したGM1[Gal
β1→3GalNacβ1→4(NeuAcα2→3)Galβ1→4Gl
cβ1→1Cer]を使用し、また酵素2の場合にはネオガ
ラトリアオシルセラミド(Neogalatriaosylceramide、G
alβ1→6Galβ1→6Galβ1→1Cer)を使用した。Substrate 1) : In the case of enzyme 1, G M1 [Gal isolated from bovine brain
β1 → 3GalNacβ1 → 4 (NeuAcα2 → 3) Galβ1 → 4Gl
cβ1 → 1Cer], and in the case of enzyme 2, neogalalatriaosylceramide, G
alβ1 → 6Galβ1 → 6Galβ1 → 1Cer) was used.
[酵素1の理化学的性質] (イ)作 用 スフィンゴ糖脂質に作用し、糖鎖とセラミドの結合を切
断してオリゴ糖とセラミドを生成する。[Physical and Chemical Properties of Enzyme 1] (a) Acts on the glycosphingolipid for production, cleaving the bond between the sugar chain and ceramide to produce oligosaccharide and ceramide.
この際、基質としては、オリゴ糖鎖にシアル酸が結合し
たガングリオシド(ganglioside)系列の酸性スフィン
ゴ糖脂質で、オリゴ糖鎖中のグルコースが直接セラミド
と結合しているもの、例えばGT1a,GD1a,GD1b,GM1,GM2,G
M3等(脂質の化学、389〜391頁、1974年、東京化学同人
社発行)が挙げられる。また、オリゴ糖鎖にシアル酸が
結合していない中性スフィンゴ糖脂質で、オリゴ糖鎖中
のグルコースが直接セラミドと結合しているもの、例え
ばラクトシルセラミド(Galβ1→4Glcβ1→1Cer)、
ネオラクトラオシルセラミド(Galβ1→4GlcNACβ1→
3Galβ1→4Glcβ1→1Cer)、フコシルペンタグリコシ
ルセラミド[Fucα1→3GalNAcα1→3(Fucα1→
2)、Galβ1→4Glcβ1→1Cer]等が挙げられる。At this time, the substrate is an acidic sphingoglycolipid of the ganglioside series in which sialic acid is bound to the oligosaccharide chain, in which glucose in the oligosaccharide chain is directly bound to ceramide, such as G T1a , G D1a , G D1b , G M1 , G M2 , G
M3, etc. (Lipid Chemistry, pages 389-391, published in 1974 by Tokyo Kagaku Dojinsha). Further, a neutral glycosphingolipid in which sialic acid is not bound to an oligosaccharide chain, in which glucose in the oligosaccharide chain is directly bound to ceramide, for example, lactosylceramide (Galβ1 → 4Glcβ1 → 1Cer),
Neolactraosylceramide (Galβ1 → 4GlcNACβ1 →
3Galβ1 → 4Glcβ1 → 1Cer), fucosylpentaglycosylceramide [Fucα1 → 3GalNAcα1 → 3 (Fucα1 →
2), Galβ1 → 4Glcβ1 → 1Cer] and the like.
(ロ)基質特異性 上記のように、酸素1は、オリゴ糖鎖中のグルコースが
直接セラミドと結合しているスフィンゴ糖脂質の、グル
コースとセラミドとの結合を特異的に切断してオリゴ糖
を生成する。即ち所謂エンドグルコシルセラミダーゼ
(endoglucosylceramidase)活性を有するが、単糖は生
成しない。換言すれば、エキソグリコシダーゼ活性は有
しない。(B) Substrate specificity As described above, oxygen 1 specifically cleaves the bond between glucose and ceramide in the glycosphingolipid in which glucose in the oligosaccharide chain is directly bonded to ceramide to form an oligosaccharide. To generate. That is, it has a so-called endoglucosylceramidase activity, but does not produce a monosaccharide. In other words, it has no exoglycosidase activity.
また、グルコースのような単糖とセラミドとが結合した
セレブロシド(cerebroside)は分解しない。Also, cerebroside, which is a combination of ceramide and a monosaccharide such as glucose, is not decomposed.
(ハ)至適pH 6.0 (ハ)安定pH 5〜9 (ホ)作用最適温は37℃であり、30〜40℃の範囲で適用
可能である。(C) Optimum pH 6.0 (c) Stable pH 5-9 (e) The optimum action temperature is 37 ° C, and it is applicable in the range of 30-40 ° C.
(ヘ)安定生 37℃で一夜間安定であり、また、凍結
乾燥品は−25℃で少なくとも数ヶ月間安定である。(F) Stable growth Stable at 37 ° C overnight, and freeze-dried products are stable at -25 ° C for at least several months.
(ト)阻害 酵素活性は銅イオン及び水銀イオンに
より阻害されるが、カルシウムイオン、マグネシウムイ
オン、バリウムイオン、亜鉛イオン及びエチレンジアミ
ン四酢酸(EDTA)による影響はない。(G) Inhibition The enzyme activity is inhibited by copper ion and mercury ion, but is not affected by calcium ion, magnesium ion, barium ion, zinc ion and ethylenediaminetetraacetic acid (EDTA).
(チ)活性化 酵素の基質に対する活性は界面活性剤
の添加により顕著に増大する。即ち、反応の際に、前記
TDCを0.5mg/ml添加すると、無添加の場合に比して反応
は2.5培に増大する。(H) Activation The activity of the enzyme on the substrate is remarkably increased by the addition of the surfactant. That is, during the reaction,
When TDC is added at 0.5 mg / ml, the reaction is increased to 2.5 times as compared to the case where TDC is not added.
(リ)分子量 “セフアデツクスG−200"のカラム(1.
5×61cm)に、0.2MのNaCl及び0.1%の“トリトンX−10
0"を含む20mMの酢酸からなる緩衝液(pH6.0)の、流速5
ml/hrで流通してゲル濾過して測定した分子量が約23万
であつた。(I) Column of molecular weight "Sefadex G-200" (1.
5 × 61 cm) with 0.2 M NaCl and 0.1% “Triton X-10
Flow rate of a buffer (pH 6.0) consisting of 20 mM acetic acid containing 0 ", 5
It had a molecular weight of about 230,000 as measured by gel filtration with circulation at ml / hr.
[酵素2の理化学的性質] (イ)作 用 スフィンゴ糖脂質に作用し、糖鎖とセラミドの結合を切
断してオリゴ糖とセラミドを生成する。[Physical and Chemical Properties of Enzyme 2] (a) Acts on the glycosphingolipid used for production, cleaves the bond between the sugar chain and ceramide to produce oligosaccharide and ceramide.
この際、基質としては、ネオガラトリアオシルセラミド
(Galβ1→6Galβ1→6Galβ1→1Cer)、ガラビオシ
ルセラミド(Galα1→4Galβ1→1Cer)等の、オリゴ
糖鎖中のガラクトースが直接セラミドと結合しているス
フィンゴ糖脂質が挙げられる。At this time, as a substrate, galactose in oligosaccharide chains such as neogalatriaosylceramide (Galβ1 → 6Galβ1 → 6Galβ1 → 1Cer) and galaviosylceramide (Galα1 → 4Galβ1 → 1Cer) directly binds to ceramide. Glycosphingolipids are known.
(ロ)基質特異性 上記のように、酸素2は、オリゴ糖鎖中のガラクトース
が直接セラミドと結合しているスフィンゴ糖脂質の、ガ
ラクトースとセラミドとの結合を特異的に切断してオリ
ゴ糖を生成する。即ち、所謂エンドガラクトシルセラミ
ダーゼ(endogalactosylceramidase)活性を有するが、
単糖は生成しない。換言すれば、エキソガラクトシター
ゼ活性は有しない。(B) Substrate specificity As described above, oxygen 2 specifically cleaves the bond between galactose and ceramide in the glycosphingolipid in which the galactose in the oligosaccharide chain is directly bonded to ceramide to form an oligosaccharide. To generate. That is, it has a so-called endogalactosylceramidase activity,
It does not produce monosaccharides. In other words, it has no exogalactosidase activity.
また、ガラクトースのような単糖とセラミドとが結合し
たセレブロシド(cerebroside)は分解しない。In addition, cerebroside, which is a combination of ceramide and a monosaccharide such as galactose, is not decomposed.
(ハ)至適pH5.0 (ハ)安定pH5〜9 (ホ)作用最適温は37℃であり、30〜40℃の範囲で適用
可能である。(C) Optimum pH 5.0 (c) Stable pH 5-9 (e) Optimal action temperature is 37 ° C, and it is applicable in the range of 30-40 ° C.
(ヘ)安定性37℃で一夜間安定であり、また、凍結乾燥
品は−25℃で少なくとも数ヶ月間安定である。(F) Stability It is stable at 37 ° C overnight, and the freeze-dried product is stable at -25 ° C for at least several months.
(ト)阻害 酵素活性は銅イオン及び水銀イオンにより
阻害されるが、カルシウムイオン、マグネシウムイオ
ン、バリウムイオン、亜鉛イオン及びエチレンジアミン
四酢酸(EDTA)による影響はない。(G) Inhibition The enzyme activity is inhibited by copper ion and mercury ion, but is not affected by calcium ion, magnesium ion, barium ion, zinc ion and ethylenediaminetetraacetic acid (EDTA).
(チ)分子量 前記酵素1の場合と同様に“セフアデツ
クスG−200"を用いたゲル濾過により測定した分子量は
約16万であつた。(H) Molecular weight As in the case of the enzyme 1, the molecular weight measured by gel filtration using "Sefadex G-200" was about 160,000.
(作 用) 本発明の酵素1又は酵素2を利用して以下の事項を解明
することができる。(Operation) The following items can be clarified by using the enzyme 1 or the enzyme 2 of the present invention.
(1)スフィンゴ糖脂質における糖鎖の役割を知ること
ができる。(1) To understand the role of sugar chains in glycosphingolipids.
(2)本酵素で切り出したオリゴ糖は、簡単な方法によ
って[3H]−標識又は2−アミノピリジンその他の蛍光
物質による標識をすることができ、このため、従来の数
百倍の感度で糖鎖の構造決定ができる。(2) The oligosaccharide cut out with this enzyme can be labeled with [ 3 H] -label or a fluorescent substance such as 2-aminopyridine by a simple method. The structure of the sugar chain can be determined.
(3)本酵素は、スフィンゴ糖脂質に対して前述のよう
に特異的に作用し、糖蛋白質に対しては作用しないの
で、微量の試料についても、糖蛋白質であるか、糖脂質
であるかの識別を容易に行なうことができる。(3) Since this enzyme specifically acts on glycosphingolipids as described above and does not act on glycoproteins, whether a trace amount of sample is a glycoprotein or a glycolipid. Can be easily identified.
(実施例) 以下に本酵素の調製法を実施例について、更に具体的に
説明する。(Example) Below, the preparation method of this enzyme is demonstrated more concretely about an Example.
実施例 (1)菌の培養と培養上清の調製 ロドコッカス エスピーG−74[Rhodococcus sp.G−7
4、微工研菌寄第8424号(FERM P−8424)]を、ポリペ
プトン0.5%、イーストエキス0.1%、塩化ナトリウム0.
2%及び誘引剤(ガングリオシド0.1%又は牛脳アセトン
パウダー1%)を含む2000mlの液体培地(pH7.0〜7.2)
を用いて28〜30℃で4日間培養した後、培養液を遠心分
離(6000r.p.mで30分間)し上清を採取した。Example (1) Culture of bacteria and preparation of culture supernatant Rhodococcus sp. G-7 [Rhodococcus sp. G-7
4, Micro-Technology Research Institute No. 8424 (FERM P-8424)], polypeptone 0.5%, yeast extract 0.1%, sodium chloride 0.
2000 ml liquid medium containing 2% and attractant (ganglioside 0.1% or bovine brain acetone powder 1%) (pH 7.0-7.2)
After culturing at 28 to 30 ° C. for 4 days, the culture solution was centrifuged (6000 rpm for 30 minutes) and the supernatant was collected.
(2)酵素の調製 上記に得た上清液1800mlにイソプロパノールを60%濃度
となるように加え、次いで遠心分離(8500r.p.mで15分
間)して生成した沈澱物を採取し、0.5%“トリトンX
−100"(非イオン界面活性剤)で抽出処理した。(2) Preparation of enzyme Isopropanol was added to 1800 ml of the supernatant obtained above so as to have a concentration of 60%, and then the mixture was centrifuged (8500 rpm for 15 minutes) to collect a precipitate, which was collected in 0.5% Triton X
Extraction treatment was performed with -100 "(nonionic surfactant).
抽出液を“セファデックスG−100"のカラム(5×85c
m)を用いてゲル濾過し、溶出液を集めて限外濾過
(“アミコンXM 50"膜使用)により濃縮した。The extract was applied to a column of "Sephadex G-100" (5 x 85c
Gel filtration was performed using m) and the eluate was collected and concentrated by ultrafiltration (using "Amicon XM 50" membrane).
濃縮液を−20℃で10倍量のイソプロパノールに加えた
後、上記と同様に遠心分離し、得られた沈澱物を0.5%
“トリトンX−100"で抽出処理し、抽出液を、50mMの酢
酸緩衝液(pH6.0、0.1%“トリトンX−100"を含む)を
用いて平衡化したDEAEセファロースFFのカラム(1.7×2
0cm)にかけた。カラムをその3倍容量の同一の緩衝液
で洗浄し、次いで塩化ナトリウムの0−0.3M直線濃度勾
配液で溶出し、溶出液を3.4ml宛順次採取し、110〜127
の画分から本発明の酵素1を得た。また、128〜142の画
分から本発明の酵素2を得た。The concentrate was added to 10 volumes of isopropanol at -20 ° C and then centrifuged as above to obtain 0.5% precipitate.
A column of DEAE Sepharose FF (1.7 ×, which had been subjected to extraction treatment with “Triton X-100” and equilibrated with 50 mM acetate buffer (pH 6.0, containing 0.1% “Triton X-100”), was used. 2
0 cm). The column was washed with 3 times its volume of the same buffer, and then eluted with a 0-0.3M linear gradient of sodium chloride, and the eluate was collected sequentially to 3.4 ml, 110-127.
The enzyme 1 of the present invention was obtained from this fraction. In addition, the enzyme 2 of the present invention was obtained from the 128 to 142 fractions.
こうして得られた酵素1及び酵素2の比活性は、夫々9.
0m単位/mg及び15.8m単位/mgであり、構造解析用試薬と
して充分使用可能であった。The specific activities of enzyme 1 and enzyme 2 thus obtained are 9.
It was 0 m unit / mg and 15.8 m unit / mg, and could be sufficiently used as a structural analysis reagent.
なお、上記酵素の比活性は前記の測定法によって測定し
た。The specific activity of the above enzyme was measured by the above measuring method.
(発明の効果) 本酵素を使用すれば、例えば細胞表層のウイルス・レセ
プター、細胞毒素(例えばコレラトキシン)のレセプタ
ー、特異的ガン抗原、発生・分化に伴う特異抗原等の構
造決定及び糖鎖の役割などを調べることができるので、
試薬として有用であり、それらに対する診断薬、治療薬
等の開発が期待される。(Effects of the Invention) By using the present enzyme, for example, structural determination of viral receptors on the cell surface, receptors for cytotoxins (eg cholera toxin), specific cancer antigens, specific antigens associated with development / differentiation, and sugar chain Since you can check the role etc.,
It is useful as a reagent, and development of diagnostic agents, therapeutic agents, etc. for them is expected.
Claims (3)
分解酵素。 (イ)作 用 糖脂質に作用し、糖鎖とセラミドの結合を切断してオリ
ゴ糖とセラミドを生成する。 (ロ)基質特異性 糖脂質の糖鎖とセラミドの結合を切断してオリゴ糖を生
成するが、単糖は生成しない。また、単糖とセラミドが
結合したセレブロシドは分解しない。 (ハ)至適 pH 5〜6 (ニ)安定 pH 5〜9 (ホ)作用適温 30〜40℃ (ヘ)安定性 37℃で一夜間安定であり、また、凍結
乾燥品は−25℃で少なくとも数ケ月間安定である。 (ト)阻害 酵素活性は銅イオン及び水銀イオンに
より阻害されるが、カルシウムイオン、マグネシウムイ
オン、バリウムイオン、亜鉛イオン及びエチレンジアミ
ン四酢酸による影響はない。 (チ)分子量 “セファデックスG−200(商標)”
のカラム(1.5x61cm)に、0.2MのNaCL及び0.1%の“ト
リトンX−100(商標)”を含む20mMの酢酸からなる緩
衝液(pH6.0)の、流速5ml/hrで流通してゲル濾過して
測定した分子量が約23万または約16万である。1. An endo-type glycolipid-degrading enzyme having the following physicochemical properties. (B) Work It acts on glycolipids and cleaves the bond between sugar chains and ceramide to produce oligosaccharides and ceramides. (B) Substrate specificity The bond between the sugar chain of glycolipid and ceramide is cleaved to form an oligosaccharide, but a monosaccharide is not formed. In addition, cerebroside in which monosaccharide and ceramide are bound is not decomposed. (C) Optimum pH 5-6 (d) Stable pH 5-9 (e) Optimum temperature 30-40 ° C (f) Stability It is stable overnight at 37 ° C, and the freeze-dried product is at -25 ° C. It is stable for at least several months. (G) Inhibition The enzyme activity is inhibited by copper ion and mercury ion, but is not affected by calcium ion, magnesium ion, barium ion, zinc ion and ethylenediaminetetraacetic acid. (H) Molecular weight "Sephadex G-200 (trademark)"
The column (1.5x61 cm) was run with a buffer (pH 6.0) consisting of 20 mM acetic acid containing 0.2 M NaCL and 0.1% "Triton X-100 (trademark)" at a flow rate of 5 ml / hr. The molecular weight measured by filtration is about 230,000 or about 160,000.
が直接結合しているスフィンゴ糖脂質である特許請求の
範囲(1)項記載のエンド型糖脂質分解酵素。2. The endoglycolipid-degrading enzyme according to claim 1, wherein the glycolipid is a glycosphingolipid in which glucose and ceramide in the sugar chain are directly bound.
ドが直接結合しているスフィンゴ糖脂質である特許請求
の範囲(1)項記載のエンド型糖脂質分解酵素。3. The endoglycolipid-degrading enzyme according to claim 1, wherein the glycolipid is a glycosphingolipid in which galactose and ceramide in the sugar chain are directly bound.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18556285 | 1985-08-23 | ||
| JP60-185562 | 1985-08-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62122587A JPS62122587A (en) | 1987-06-03 |
| JPH0789914B2 true JPH0789914B2 (en) | 1995-10-04 |
Family
ID=16172978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15099986A Expired - Fee Related JPH0789914B2 (en) | 1985-08-23 | 1986-06-27 | Endo type glycolipid degrading enzyme |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0789914B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047337A (en) * | 1987-10-23 | 1991-09-10 | Li Su Chen | Ceramide-glycanase |
| DE69635849T2 (en) * | 1995-06-29 | 2006-10-19 | Takara Bio Inc., Otsu | Gene encoding endoglycoceramidase |
-
1986
- 1986-06-27 JP JP15099986A patent/JPH0789914B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62122587A (en) | 1987-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0005751B1 (en) | Hyaluronidase and its production | |
| DE69120489T2 (en) | Highly sensitive test method for myo-inositol and composition for the execution thereof | |
| AU722636B2 (en) | Method for quantitative determination of 1,5-anhydroglucitol | |
| US4997760A (en) | Novel ganglioside ceramidase isolated from Nocardia and process for producing same | |
| US5143841A (en) | Ganglioside ceramidase and process for producing same | |
| JPH0789914B2 (en) | Endo type glycolipid degrading enzyme | |
| US5234828A (en) | Process for producing novel heat-resistant β-galactosyltransferase | |
| EP0456986B1 (en) | Heat resistant beta-galactosyltransferase, its production process and its use | |
| US5756314A (en) | Method for preparation of monosialoganglioside GM1 | |
| JP2660722B2 (en) | Microorganism | |
| JP2688854B2 (en) | Method for producing α-galactosidase with strong transglycosylation activity | |
| JPH0759587A (en) | Method for producing sugar or complex sugar | |
| JPH07107988A (en) | Production of lysoglycolipid | |
| JP2970932B2 (en) | Novel heat-stable β-galactosyltransferase, its production method and its use | |
| Fukuoka et al. | Extracellular lipopolysaccharide production by Erwinia carotovora | |
| JPH064019B2 (en) | Microorganism | |
| JP2699078B2 (en) | Muscin degrading enzyme and its production method | |
| JP3468626B2 (en) | β-glucosidase and method for producing the same | |
| JP2854541B2 (en) | Hydrolysis method of sugar compounds | |
| JP3752295B2 (en) | Endo-β-N-acetylglucosaminidase and method for producing the same | |
| JPH0398583A (en) | New alpha-l-fucosidase | |
| JPH0358269B2 (en) | ||
| JPH05304955A (en) | Novel neuraminidase, method for producing the same and method for producing sialic acid-binding compound using the same | |
| JP3532937B2 (en) | Novel NADPH-dependent diaphorase having high heat resistance and method for producing the same | |
| TW202138557A (en) | Oligosaccharide oxidase, preparing method thereof and method of conversion into chito-oligochitosan acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |